Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - tamoxifen citrate - oral tablet - 40mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tamoxifen citrate - oral tablet - 40mg

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - tamoxifen citrate 15.2mg equivalent to tamoxifen 10 mg - tablet - 10 mg - active: tamoxifen citrate 15.2mg equivalent to tamoxifen 10 mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose povidone sodium starch glycolate

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg - tablet - 20 mg - active: tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate microcrystalline cellulose povidone sodium starch glycolate

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - tamoxifen citrate - oral tablet - 10mg

Estados Unidos - inglés - NLM (National Library of Medicine)

fortovia therapeutics inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 20 mg in 10 ml - soltamox is indicated for the treatment of adult patients with estrogen receptor-positive metastatic breast cancer. soltamox is indicated: - for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer - to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer. in adult women with dcis, following breast surgery and radiation, soltamox is indicated to reduce the risk of invasive breast cancer [see boxed warning and clinical studies (14.3)] . soltamox is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer.[see boxed warning and clinical studies (14.4)] . - soltamox is contraindicated in patients with known hypersensitivity (e.g., angioedema, serious skin reactions) to tamoxifen or any other soltamox ingredient [see adverse reactions (6.2)] . - soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of d

Canadá - inglés - Health Canada

teva canada limited - tamoxifen (tamoxifen citrate) - tablet - 10mg - tamoxifen (tamoxifen citrate) 10mg - antineoplastic agents

Canadá - inglés - Health Canada

teva canada limited - tamoxifen (tamoxifen citrate) - tablet - 20mg - tamoxifen (tamoxifen citrate) 20mg - antineoplastic agents

Canadá - inglés - Health Canada

mylan pharmaceuticals ulc - tamoxifen (tamoxifen citrate) - tablet - 10mg - tamoxifen (tamoxifen citrate) 10mg - antineoplastic agents

Canadá - inglés - Health Canada

mylan pharmaceuticals ulc - tamoxifen (tamoxifen citrate) - tablet - 20mg - tamoxifen (tamoxifen citrate) 20mg - antineoplastic agents